PARTICIPATE IN THE DEBATE AND FUTURE ROADMAP

The Forum is an open space for all viewpoints—support, rebuttal, and real-world experience. All contributions are valued and will be publicly summarized on a periodic basis to help drive change.

How to participate 

  1. Submit your viewpoint / supporting letter / rebuttal
    Submit via the form below (or email directly to Vien Gut).

  2. Join the public discussion
    Share on X/LinkedIn with the hashtags:
    #HienThucHoaMucTieuChuaKhoiGut #GoutCureTarget

  3. Submit a dedicated open letter
    Guideline experts, OMERACT, and G-CAN members are especially invited to submit supporting letters for public posting.

Future roadmap (proposed) 

Phase 1 (3–6 months): Collect and synthesize viewpoints from the community; publish periodic public summaries.

Phase 2 (6–12 months): If momentum builds, organize a virtual roundtable with guideline experts and OMERACT/G-CAN.

Phase 3: Consolidate into a joint letter or position paper and submit to guideline task forces (EULAR, ACR, and national societies).

Final goal 

To contribute to updated guideline versions, unblock the foundational chain, and make the goal of curing gout a global reality.

Colleagues—please participate today to help realize a goal that pathophysiological principles have already made possible for 20 years.

Participation form: [Google Form link or a form on the website]

Thank you for your support.

End of the Forum – this is the final section of the document series.

BIỂU MẪU ĐỒNG THUẬN CHUYÊN GIA 2

B. FOUNDATIONAL STATEMENT (to define the scope of consensus)

I confirm that I have read and understood the consensus proposal based on the following foundational points:

B1. Definition of “raising the standard ceiling”:
Remission (as defined by OMERACT 2016 / G-CAN 2024/2025) is maintained as the mandatory minimum foundation, with the addition of a higher tier: the absence of monosodium urate (MSU) crystals (crystal-free) at the time of assessment by joint ultrasound according to OMERACT standards, thereby forming the basis for a conditional standard of gout cure.

B2. Definition of “conditional gout cure”:
“Cure at the time of assessment” (crystal-free at assessment) does not equate to permanent cure and requires maintenance conditions (particularly urate-lowering therapy, ULT) to prevent re-deposition.

C. CORE CONSENSUS CONTENT (tick selection + level of agreement)

C1. Consensus on the “two-tier structure”
Clinical remission represents the minimum foundation; Conditional Cure constitutes the upper-tier standard.

C2. Consensus on the “cure-at-assessment status”
Acceptance of the term/concept: “Conditional gout cure = crystal-free at assessment,” with the mandatory accompanying statement: “not a permanent cure.”

C3. Consensus on the “verification tool”
Joint ultrasound (US) according to OMERACT standards is the mandatory verification tool for the “upper-tier standard.”

C4. Consensus on “not selecting DECT as a mandatory requirement”
DECT is not included as a mandatory criterion at this consensus stage; it is considered optional/supplementary at centers with adequate capability.

C5. Consensus on “maintenance conditions”
Standardized communication is required to state that: without maintenance of ULT, serum urate (sUA) rises → crystal re-deposition → disease recurrence.

C6. Consensus on “operational target of centers”
The long-term operational endpoint should be defined as crystal-free status; maintaining sUA below threshold is a necessary condition to achieve and sustain this endpoint.

D. CONSENSUS OUTPUTS OF THE FORUM

E. CONDITIONS / MODIFICATIONS / EXPERT COMMENTS (if any)

F. ETHICAL COMMITMENT – TRANSPARENCY

  • I confirm that this consensus opinion is provided independently and without coercion.

  • I have declared conflicts of interest (COI) in Section A.8.

  • I authorize the Forum Secretariat to cite my name/affiliation in the consensus list (if required):

G. CONFIRMATION